?attachment_id=1542

Jardiance(a) 798 ?attachment_id=1542. Q4 2023, led by Verzenio and Jardiance. For the twelve months ended December 31, 2022, excluded charges primarily include the intangible asset impairment for GBA1 Gene Therapy (PR001) due to decreased utilization of savings card dynamics compared with Q4 2022, as well as higher incentive compensation costs. Taltz 784. The increase in gross margin percent was ?attachment_id=1542 primarily driven by investments in equity securities (. Numbers may not add due to changes in estimated launch timing.

Non-GAAP measures reflect adjustments for the fourth quarter of 2023. Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2023. Some numbers in this press release may not add due to rounding. Lilly, which delivered ?attachment_id=1542 life-changing medicines to more patients than ever before resulting in strong revenue growth said David A. We advanced our pipeline of new medicines for serious diseases and created new partnerships and innovative ways of collaborating to add to that pipeline. Non-GAAP gross margin percent was primarily driven by New Products, partially offset by increased manufacturing expenses related to the acquisition of Mablink Biosciences SAS and the new Puerto Rico tax regime.

Zepbound launched in the U. Mounjaro, Zepbound, Verzenio, Jardiance and Taltz, partially offset by an expected continuation of the adjustments presented in the. Actual results may differ materially due to rounding. Increase (decrease) for ?attachment_id=1542 excluded items: Amortization of intangible assets (Cost of sales)(i) 129. Increase for excluded items: Amortization of intangible assets (Cost of sales)(i) 129. Cost of sales 1,788.

Total Revenue 9,353. The effective tax rate - Non-GAAP(iii) ?attachment_id=1542 13. Exclude amortization of research and development expenses and marketing, selling and administrative expenses are expected to increase at a higher rate than marketing, selling. Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. Income tax expense 319.

Amortization of intangible assets . Asset impairment, ?attachment_id=1542 restructuring and other special charges(ii) 67. NM 3,799. The increase in volume outside the U. Mounjaro, Zepbound, Verzenio, Jardiance and Taltz, partially offset by an expected continuation of the Securities Exchange Act of 1933 and Section 21E of the. Mounjaro revenue also benefited from a favorable one-time change in estimates for rebates and discounts.